CA
AVEO

Centerpoint Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Centerpoint Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed – – 316
2021
Q1 		$0 Buy
+50
New +$431 ﹤0.01% 288

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Centerpoint Advisors's AVEO Position: Q2 2021 in Review

Centerpoint Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 50 shares.

Centerpoint Advisors first reported a position in AVEO in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

  • Centerpoint Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Centerpoint Advisors sold 50 AVEO Pharmaceuticals, Inc. shares in Q2 2021.
  • Centerpoint Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Centerpoint Advisors's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q1 2021.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Centerpoint Advisors's 13F filing for Q2 2021, filed 26 Jul 2021.